http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-2018002242-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f2e8d4f980eac450fe75cee98ac0758 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0808 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14 |
| filingDate | 2016-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c07d461422b01a7a9f2b48e66dd7d4fa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f68470b2d3a1f6d37d512e7df6e5b67 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b51c0597c93cb410ec4e2b46074f1744 |
| publicationDate | 2018-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MX-2018002242-A |
| titleOfInvention | PIPERIDINOBENZODIAZEPINA COMPOUNDS WITH ANTIPROLIFERATIVE ACTIVITY. |
| abstract | The invention relates to pyridinobenzodiazepines (PDD) comprising three fused rings of 6-7-6 members linked to aromatic groups, and pharmaceutically acceptable salts thereof, which are useful as medicaments, such as antiproliferative agents. The PDDs can be represented by the formula (I): and salts and solvates thereof, wherein the dotted lines indicate the optional presence of a double bond between one or more of C1 and C2, C2 and C3, and C3 and C4 ; R1 and R2 are substituent groups; R3 is selected from H, C1-12 alkyl and CH2Ph; R4 is selected from optionally substituted phenyl and C5-9 heteroaryl groups, with the proviso that the optionally substituted C5-9 heteroaryl is not indolyl; R19 is selected from H and (CH2) t-NR20R21; Y1 is N or CH; Y2 is N or CH; and where at least one of Y1 and Y2 is CH; p is 0 or 1; X1 is a connector group; L is a linker group; X2 is a connector group or is absent; q is selected from 0, 1, 2, 3, 4, 5 and 6; A is selected from: for each group A1, one of Y3 and Y4 is selected from N-R17, S and O; and the other of Y3 and Y4 is CH; and Y5 is selected from CH, N, S and COH; for each group A2, one of Y6 and Y7 is independently selected from N and CH; and the other of Y6 and Y7 is CH; R13, R14, R17, R, 20 and R, 21 are independently selected from H and C1-6 alkyl; and, either: (i) R5 and R6 together form a double bond; (ii) R5 is H and R6 is OH; or (iii) R5 is H and R6 is OC1-6 alkyl; with the proviso that when p is 0 and A is A1, then: (a) for at least one A1 group one of Y3 and Y4 is selected from S and O; or (b) for at least one group A1, Y5 is S; or (c) R4 is not pyrrolyl, imidazolyl, optionally substituted pyrrolyl or optionally substituted imidazolyl. |
| priorityDate | 2015-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.